What is the BPC-157 + GHK-Cu stack? BPC-157 + GHK-Cu is a two-component peptide research preparation containing BPC-157 and the copper-binding peptide complex GHK-Cu. Unlike a named, clinically validated drug formulation, the combination is primarily a research-market formulation. A commonly encountered commercial composition is 10 mg BPC-157 + 50 mg GHK-Cu, but the name itself does not guarantee a standardized ratio.
Important distinction: Evidence concerning BPC-157 or GHK-Cu individually should not be interpreted as evidence that the BPC-157 + GHK-Cu combination has been shown to be effective or safe. The mathematical concentration calculations on this page describe mass-per-volume relationships only; they are not a dosing or administration protocol.
Common Name
BPC-157 + GHK-Cu
Components
BPC-157 + GHK-Cu
Common Market Form
10 mg + 50 mg
Standardized?
No
Combination Evidence
No established clinical evidence
BPC-157 Evidence
Limited human data
GHK-Cu Evidence
Mechanistic / dermal research
Regulatory Status
Research context; not an established approved combination
BPC-157 + GHK-Cu Composition Diagram
What Is BPC-157 + GHK-Cu?
BPC-157 + GHK-Cu describes a two-compound research preparation rather than a single peptide molecule. BPC-157 is a synthetic 15-amino-acid peptide, while GHK-Cu is a copper-associated complex involving the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). The two therefore remain chemically distinct components even when supplied together in one vial.
Current research-market listings show preparations containing approximately 50 mg GHK-Cu and 10 mg BPC-157. Other ratios or quantities may exist, so the actual vial label or batch documentation should always be treated as the controlling source for a particular preparation.
Terminology: "BPC-157 + GHK-Cu" is best treated as a descriptive combination name or commercial research formulation, not as the name of a scientifically standardized pharmaceutical product.
What's in BPC-157 + GHK-Cu?
01
BPC-157
Synthetic pentadecapeptide
BPC-157 is a 15-amino-acid peptide that has been investigated extensively in preclinical research involving gastrointestinal, vascular, tendon, ligament and tissue-repair models.
Evidence status: Primarily preclinical, with a very small and limited human evidence base.
02
GHK-Cu
Copper-associated tripeptide complex
GHK-Cu is the copper-associated form of GHK, a tripeptide studied in fibroblast, extracellular-matrix, wound-healing and dermal research.
Evidence status: Considerable mechanistic and dermal research exists, but evidence for this specific two-peptide combination is a separate question.
Common BPC-157 + GHK-Cu Formulations
There is no universal pharmaceutical formulation of BPC-157 + GHK-Cu. One frequently encountered research-market preparation contains 50 mg GHK-Cu and 10 mg BPC-157, for 60 mg total peptide material. This should be described as a commonly encountered formulation, not a clinically standardized formulation.
Component
Example Mass
Mass Share
Interpretation
GHK-Cu
50 mg
83.33%
Largest mass component in this example.
BPC-157
10 mg
16.67%
Smaller mass component in this example.
Total
60 mg
100%
Total mass only; it must not be substituted for either component's individual concentration.
Why the distinction matters: If 60 mg total material is dissolved in a volume of liquid, the resulting 60 mg/mL figure would describe the combined mass concentration. It would not mean that BPC-157 is 60 mg/mL or that GHK-Cu is 60 mg/mL.
Why Are BPC-157 and GHK-Cu Combined in Research or Market Practice?
The conceptual rationale for combining them comes from their separate research areas: BPC-157 has been investigated in tissue-repair and vascular models, while GHK-Cu has been investigated in extracellular-matrix, fibroblast and wound-remodeling research. These complementary research themes can explain why a combined research preparation may be marketed.
However, a mechanistic rationale is not the same thing as demonstrated combination efficacy. It does not establish that the two compounds act synergistically, additively, or even compatibly in a single formulation.
Evidence for BPC-157
BPC-157 has a substantial preclinical literature, but the translation to human evidence remains limited. A recent review identified only a small number of published human studies, with fewer than 30 total subjects across the reported studies and no randomized controlled trial establishing therapeutic efficacy. :contentReference[oaicite:2]{index=2}
A 2025 pilot study involving two participants examined intravenous BPC-157 exposure and reported no measurable adverse effects during the study, but the sample was extremely small and the authors themselves called for additional research. This type of pilot safety observation cannot establish efficacy or general safety for broader populations or routes of exposure. :contentReference[oaicite:3]{index=3}
Evidence classification: BPC-157 should not be presented as a clinically established treatment based on its current human evidence.
Evidence for GHK-Cu
GHK-Cu has a longer research history than BPC-157, particularly in dermal, fibroblast, extracellular-matrix and tissue-remodeling research. Laboratory studies have reported effects on collagen-related processes and glycosaminoglycan synthesis, while reviews have described a broad body of mechanistic and skin-related research. :contentReference[oaicite:4]{index=4}
Importantly, evidence for GHK-Cu in topical or experimental contexts should not automatically be transferred to a BPC-157 + GHK-Cu injectable co-formulation. Route, formulation, purity, concentration, stability and exposure can materially change the scientific question.
Formulation warning: FDA materials published in 2026 specifically note limited human safety information for injectable GHK-Cu and identify potential immunogenicity concerns related to peptide aggregation and impurities. :contentReference[oaicite:5]{index=5}
Has the Complete BPC-157 + GHK-Cu Combination Been Clinically Studied?
Direct answer: No established controlled human study has demonstrated the efficacy or safety of the complete BPC-157 + GHK-Cu combination as a standardized formulation.
The scientific literature should therefore be divided into two separate evidence categories: studies of BPC-157 alone and studies of GHK-Cu alone. Those studies do not become combination evidence simply because both compounds appear in a commercial research vial.
What the component literature can tell us
BPC-157 has extensive preclinical research.
BPC-157 has limited human data.
GHK-Cu has a substantial mechanistic and dermal literature.
The two compounds have distinct molecular identities.
What it cannot tell us
That the combination is clinically effective.
That the combination is synergistic.
That the combination is safer than either component alone.
That one shared formulation is chemically or biologically validated.
BPC-157 + GHK-Cu Reconstitution & Concentration
For a multi-component vial, the concentration of each component is calculated separately. Both components occupy the same final liquid volume, but each retains its own original mass.
Component concentration = component mass (mg) ÷ final liquid volume (mL)
For the example formulation used on this page:
GHK-Cu = 50 mg
BPC-157 = 10 mg
Therefore, if the final liquid volume is 5 mL:
GHK-Cu = 50 mg ÷ 5 mL = 10 mg/mL BPC-157 = 10 mg ÷ 5 mL = 2 mg/mL
Do not add the component masses and assign that total to each ingredient. A 60 mg total mass in 5 mL corresponds to 12 mg/mL combined mass concentration, but that does not mean either GHK-Cu or BPC-157 individually has a concentration of 12 mg/mL.
How BAC-Water Volume Changes Every Component's Concentration
Changing the liquid volume changes the concentration of every component. The component masses do not change simply because a different volume is used.
Final Liquid Volume
GHK-Cu Mass
GHK-Cu Concentration
BPC-157 Mass
BPC-157 Concentration
1 mL
50 mg
50 mg/mL
10 mg
10 mg/mL
2 mL
50 mg
25 mg/mL
10 mg
5 mg/mL
3 mL
50 mg
16.67 mg/mL
10 mg
3.33 mg/mL
5 mL
50 mg
10 mg/mL
10 mg
2 mg/mL
10 mL
50 mg
5 mg/mL
10 mg
1 mg/mL
Values are mathematical examples based on a hypothetical 50 mg GHK-Cu + 10 mg BPC-157 vial. They do not establish a recommended volume, concentration, route, dose, frequency, or clinical protocol.
Concentration Changes With Final Liquid Volume
1 mL GHK-Cu: 50 mg/mL BPC-157: 10 mg/mL
2 mL GHK-Cu: 25 mg/mL BPC-157: 5 mg/mL
3 mL GHK-Cu: 16.67 mg/mL BPC-157: 3.33 mg/mL
5 mL GHK-Cu: 10 mg/mL BPC-157: 2 mg/mL
10 mL GHK-Cu: 5 mg/mL BPC-157: 1 mg/mL
Worked Mathematical Examples
Example 1 — 2 mL final volume
GHK-Cu: 50 mg ÷ 2 mL = 25 mg/mL BPC-157: 10 mg ÷ 2 mL = 5 mg/mL
Example 2 — 3 mL final volume
GHK-Cu: 50 mg ÷ 3 mL = 16.67 mg/mL BPC-157: 10 mg ÷ 3 mL = 3.33 mg/mL
Example 3 — 5 mL final volume
GHK-Cu: 50 mg ÷ 5 mL = 10 mg/mL BPC-157: 10 mg ÷ 5 mL = 2 mg/mL
Calculation rule: Always calculate each compound independently. The shared liquid volume is the denominator; the original mass of the individual component is the numerator.
Need to Calculate Another Vial or BAC-Water Volume?
Use the BacScience Universal BAC Water Calculator for single-compound mathematical calculations. For a multi-component vial, calculate each component separately using its stated mass and the same final liquid volume.
A single-compound calculator can use one mass value and one final volume. A multi-component vial requires a separate calculation for every compound. This is particularly important when the components have substantially different starting masses.
Calculation
Correct Method
Incorrect Shortcut
GHK-Cu
50 mg ÷ final mL
60 mg ÷ final mL
BPC-157
10 mg ÷ final mL
60 mg ÷ final mL
Total material
50 mg + 10 mg = 60 mg
Use total as each individual concentration
Research Status at a Glance
BPC-157
Extensive preclinical literature; limited human evidence; no established clinical efficacy for this combination.
GHK-Cu
Longstanding mechanistic, fibroblast, extracellular-matrix and dermal research.
Combination
The individual evidence should not be presented as evidence for BPC-157 + GHK-Cu combination efficacy.
Research Limitations
Commercial formulations may differ in component mass and ratio.
A formulation label is not equivalent to a clinical validation study.
The compatibility and stability of a particular co-formulation require formulation-specific analytical data.
Concentration mathematics does not establish an appropriate human dose, route, frequency or treatment schedule.
Research-grade material and a regulated pharmaceutical product are not interchangeable concepts.
Regulatory & Safety Considerations
BPC-157 + GHK-Cu should not be described as an FDA-approved combination therapy. The existence of a commercial research blend does not establish regulatory approval, clinical efficacy, pharmaceutical equivalence or human safety.
FDA's 2026 materials concerning BPC-157 describe insufficient clinical safety information and potential immunogenicity concerns related to peptide aggregation and impurities. FDA materials concerning injectable GHK-Cu likewise identify limited human safety information and potential immunogenicity concerns. :contentReference[oaicite:6]{index=6}
BPC-157 + GHK-Cu FAQ
What is BPC-157 + GHK-Cu?
It is a two-component research preparation containing BPC-157 and GHK-Cu. It should be treated as a formulation or combination name, rather than a standardized pharmaceutical product.
Is BPC-157 + GHK-Cu a standardized peptide stack?
No. Research-market preparations can use different masses or ratios. A commonly encountered example is 50 mg GHK-Cu plus 10 mg BPC-157, but the actual vial specification should always be checked.
What are the ingredients in a 50 mg / 10 mg example?
The example contains 50 mg GHK-Cu and 10 mg BPC-157, for 60 mg combined peptide material.
Has the complete BPC-157 + GHK-Cu combination been clinically studied?
There is no established controlled clinical evidence demonstrating efficacy or safety for the complete combination as a standardized formulation. Component studies should not be presented as combination studies.
Does adding more BAC water change the amount of peptide?
No. In a mathematical concentration model, the component mass remains unchanged while the concentration decreases as the final liquid volume increases.
How do I calculate GHK-Cu concentration?
Divide the stated GHK-Cu mass in milligrams by the final liquid volume in milliliters. For example, 50 mg divided by 5 mL equals 10 mg/mL. This is a mathematical concentration calculation, not a recommended administration protocol.
How do I calculate BPC-157 concentration?
Divide the stated BPC-157 mass by the final liquid volume. For example, 10 mg divided by 5 mL equals 2 mg/mL.
Can I use the total 60 mg as the concentration of each peptide?
No. The 60 mg value is the combined mass. GHK-Cu and BPC-157 must be calculated separately because they have different starting masses.
Is BPC-157 + GHK-Cu the same as GLOW?
No. GLOW is commonly described as a three-component research blend containing GHK-Cu, BPC-157 and TB-500. A BPC-157 + GHK-Cu preparation contains only two components and should not automatically be labeled GLOW. Current market sources commonly describe GLOW as 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500.
Last reviewed: September 2026 Research status and formulation information should be rechecked periodically because commercial peptide formulations and regulatory positions can change.
Choosing a selection results in a full page refresh.
